scholarly journals Isolation and characterization of Wharton’s jelly-derived multipotent mesenchymal stromal cells obtained from bovine umbilical cord and maintained in a defined serum-free three-dimensional system

2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Tereza C Cardoso ◽  
Heitor F Ferrari ◽  
Andrea F Garcia ◽  
Juliana B Novais ◽  
Camila Silva-Frade ◽  
...  
2008 ◽  
Vol 36 (8) ◽  
pp. 1035-1046 ◽  
Author(s):  
Antonio Sorrentino ◽  
Manuela Ferracin ◽  
Germana Castelli ◽  
Mauro Biffoni ◽  
Giada Tomaselli ◽  
...  

2013 ◽  
Vol 33 (9) ◽  
pp. 1151-1154 ◽  
Author(s):  
Armando de M. Carvalho ◽  
Ana Lucia M. Yamada ◽  
Juliana R.B. Martins ◽  
Leandro Maia ◽  
Marjorie A. Golim ◽  
...  

The objective of the study was to isolate, cultivate and characterize equine peripheral blood-derived multipotent mesenchymal stromal cells (PbMSCs). Peripheral blood was collected, followed by the isolation of mononuclear cells using density gradient reagents, and the cultivation of adherent cells. Monoclonal mouse anti-horse CD13, mouse anti-horse CD44, and mouse anti-rat CD90 antibodies were used for the immunophenotypic characterization of the surface of the PbMSCs. These cells were also cultured in specific media for adipogenic and chondrogenic differentiation. There was no expression of the CD13 marker, but CD44 and CD90 were expressed in all of the passages tested. After 14 days of cell differentiation into adipocytes, lipid droplets were observed upon Oil Red O (ORO) staining. Twenty-one days after chondrogenic differentiation, the cells were stained with Alcian Blue. Although the technique for the isolation of these cells requires improvement, the present study demonstrates the partial characterization of PbMSCs, classifying them as a promising type of progenitor cells for use in equine cell therapy.


Author(s):  
G. T. Sukhikh ◽  
A. V. Degtyareva ◽  
D. N. Silachev ◽  
K. V. Gorunov ◽  
I. V. Dubrovina ◽  
...  

The article presents the results of intravenous transplantation of allogeneic multipotent mesenchymal stromal cells, derived from a human umbilical cord, to a child with Crigler–Najjarsyndrome type I during the first 2 years of life. The therapy is aimed at reduction of the duration of phototherapy while maintaining a safe level of serum bilirubin.In this study, a five-day-old child with the bilirubin level of 340 µmol/l was treated with phototherapy for 16–18 hours daily in the neonatal period. Then, phototherapy was reduced to 14–16 hours. The level of bilirubin varied from 329 to 407 μmol/l. At the age of 2 months, it was decided to use multipotent mesenchymal stromal cells with a significant decrease in the duration of phototherapy up to 2 hours a day. During the observation period (2 years at the time of writing this article) the child received 6 injections of multipotent mesenchymal stromal cells. A positive effect developed within 4–7 days after administration and persisted for 2–3 months. There were no side effects or complications during and after transplantation.Thus, intravenous transplantation of multipotent mesenchymal stromal cells is an effective treatment of Crigler–Najjar syndrome type I; it reducesthe need for phototherapy,significantly improvesthe quality of life of the patients and prolongstheir life with native liver. 


2020 ◽  
Vol 22 ◽  
pp. 02014
Author(s):  
Oleg Makeyev ◽  
Arteom Korotkov ◽  
Svetlana Kostyukova ◽  
Daria Sichkar ◽  
Elizaveta Yakovleva

Damage to the cartilage surface of the joints is a common pathology. Conventional drug therapies are effective only at the initial stage of the disease and only slow down the further development of the disease. In subsequent stages, it is necessary to apply surgical methods from replacing a defect to complete prosthetics of a damaged joint. In order to replace defects in cartilage tissue, a three-dimensional bioequivalent was created based on autologous multipotent mesenchymal stromal cells.


Sign in / Sign up

Export Citation Format

Share Document